In canine osteoarthritis management, amantadine hydrochloride is incorporated as an immediate-release tablet where the target dose of 3–5 mg/kg given every 12 to 24 hours drives the selection of a 100 mg compressed solid. Direct compression is preferred over wet granulation because the primary amine functional group of amantadine can undergo Maillard-type degradation in the presence of reducing sugars and residual moisture. A direct-compression matrix contains microcrystalline cellulose as a plastically deforming filler and croscarmellose sodium as a superdisintegrant at 2% to 4% w/w; anhydrous dibasic calcium phosphate may replace up to 30% of the filler to reduce hygroscopicity. The API fraction is milled to a particle size where at least 90% of the volume passes a 250 µm sieve, otherwise content uniformity under USP <905> may drift outside the acceptance value of 15. Lubrication with magnesium stearate is maintained at 0.5% w/w and mixing time is capped at 5 minutes because over-lubrication retards dissolution velocity in USP <711> Apparatus 2. Rotary tablet press settings observed on production-scale equipment include a compression force range of 8–12 kN and a hardness target of 60–100 N; tablets failing to exceed 60 N exhibit edge damage during transparent PVC/PVDC blister filling, while hardness above 100 N can extend disintegration beyond 15 minutes when lower-croscarmellose formulations are used. Pharmacopeial friability testing requires loss not more than 1.0%. The finished tablet is a non-sterile compounded preparation intended for oral administration to non-food companion animals under veterinary oversight.

What Limits Low-Dose Capsule Blending for Feline Amantadine HCl Compounding?

Low-dose capsule compounding for feline chronic pain exposes a content uniformity boundary because the target dose per unit may fall below 25 mg when a 3 mg/kg dose is required for a 3–5 kg cat. The selected direct-fill process uses geometric dilution rather than wet massing: the amantadine hydrochloride powder is first triturated with an equal mass of pregelatinized starch, then passed through a 500 µm screen into a V-blender operating at 25 rpm for 15 minutes. High-shear mixing is deliberately avoided because it raises powder temperature above 40 °C and mobilises residual moisture, accelerating brown discolouration if trace reducing sugars are present. Gelatin capsule shells are selected over hydroxypropyl methylcellulose when the fill contains less than 3% water, but hygroscopic starch grades can transfer moisture to the shell and cause insufficient brittleness; therefore capsule storage at 20–25 °C and ≤40% RH is specified. In-process verification is performed under USP <905>, with blend samples taken from 10 positions; an individual content value outside 85–115% or an RSD greater than 6.0% requires re-milling of the API before re-blending. The finished capsule is a non-sterile compounded preparation and is assigned a beyond-use date according to USP <795>; for oral capsules in the absence of site-specific stability data, the conservative dating window does not exceed 180 days in tightly closed high-density polyethylene containers. Published pharmacokinetic data for amantadine capsules in cats are limited; therefore dissolution acceptance is often adapted from the human tablet monograph rather than from a validated feline-specific specification.

When an Injectable Solution Is Compounded from Amantadine HCl API, Terminal Sterilization and pH Control Are the Governing Constraints

Sterile injectable preparations of amantadine hydrochloride are not licensed veterinary products in most markets, and their preparation from bulk API is confined to hospital pharmacy compounding under a risk-based quality system. The active substance is dissolved in Water for Injection to a nominal concentration of 10 mg/mL and adjusted with citric acid or dilute hydrochloric acid to a pH between 4.0 and 5.5; below 4.0 the risk of container-closure hydrolysis increases for uncoated butyl rubber stoppers, while above 5.5 the protonated primary amine can nucleophilically attack trace aldehyde impurities present in polysorbate-based stabilisers. Filtration is conducted through a 0.22 µm polyethersulfone membrane that meets the bacterial challenge criteria of ASTM F838-20; filter integrity testing by bubble point or diffusive flow is performed before and after filling. Terminal sterilisation at 121 °C for 15 minutes may be validated only after forced degradation confirms no rise in related substances beyond the assigned threshold of 0.5% for any unspecified impurity; if thermal exposure induces more than 2% total degradation, aseptic filtration without terminal heat is adopted. The fill is conducted in an ISO Class 5 laminar airflow environment within an ISO Class 7 cleanroom under USP <797>; filled vials are inspected for particulate matter per USP <788>. Because amantadine is eliminated primarily by renal clearance in mammals, any injectable protocol must include renal function monitoring before repeat dosing; published veterinary parenteral dose data for this specific configuration is limited to institutional case series rather than fixed-label recommendations.

Because small-stature veterinary patients require exact weight-based titration, a compounded oral solution at a nominal concentration of 10 mg/mL is prepared by dissolving amantadine hydrochloride in purified water containing a non-reducing preservative system. The vehicle is buffered to pH 4.0–5.0 because the drug remains ionised in acidic solution, reducing adsorption to polyethylene terephthalate or glass containers and suppressing microbial growth challenges associated with neutral pH sugar-containing syrups. Sucrose and sorbitol bulking agents are excluded from the primary vehicle unless a stability study demonstrates no increase in related substances under 40 °C/75% RH for 30 days; this is a conservative screen for primary amine reactivity with aldehyde-forming sugars. The solution is filled into amber glass or opaque high-density polyethylene bottles with child-resistant closures, and a graduated oral syringe is supplied as a measuring device because household spoons introduce dosing deviations greater than 20% in cats below 3 kg. Storage is assigned at 20–25 °C with light protection; if no site-specific preservative efficacy data are available, the beyond-use date is limited to 14 days refrigerated under USP <795> for oral aqueous preparations. Cats with reduced renal clearance may accumulate the drug; published monitoring guidance recommends assessing serum creatinine and urine specific gravity before dose escalation. The compounded solution is dispensed as an unapproved veterinary product and is labelled with the active concentration, lot number, and storage range rather than a commercial trade name.

Granulated Powder Intermediates Require Dry Granulation When Reducing-Sugar Excipients Are Excluded.

Dry granulation by roller compaction is selected over wet granulation when the API contains a primary amine group and the only available fillers include polyol-based binders with trace aldehyde levels. The amantadine hydrochloride powder is pre-blended with microcrystalline cellulose and crospovidone at a drug load of 20% w/w in a batch size appropriate for a roller compactor with 10 cm × 5 cm rolls. Compaction pressure is stepped from 20 kN to 40 kN until the resulting ribbons fracture into granules with a particle-size distribution between 100 µm and 800 µm; granules below 100 µm are recycled to the feed hopper to avoid excessive fines that promote segregation during sachet filling. A lubricant-free formulation is preferred at the granulation stage because intragranular magnesium stearate can reduce compactibility and extend disintegration beyond the target 10 minutes in the finished granule. The dried granules are packaged as unit-dose sachets or incorporated into chewable matrices by low-shear mixing with a lipid binder at 35–40 °C; the lipid binder temperature is kept below the melting point of amantadine hydrochloride and below the glass transition of any polymeric taste-masking coat. In-process moisture is controlled at NMT 3.0% by Karl Fischer titration because free water in the presence of amine-functionalised drug and starch-derived glidants can produce pH shifts that alter dissolution. The granule intermediate is tested for bulk density and flow using USP <616>, and loss on drying is determined according to USP <731>. The finished granules are intended for extemporaneous sprinkling onto a small amount of canned renal or senior diets, but they are not sterilised and are not suitable for nasogastric administration without full dispersion through a 1.2 mm sieve.

Premix Dilution for Non-Food Avian Quarantine and Regulatory Boundaries

In non-food avian quarantine units, premix manufacture follows a segregated workstream because the final dilution may be as low as 10 g/kg when a target dose of 2–3 mg/kg is delivered through a complete feed. Amantadine hydrochloride is first milled to a volume median diameter below 300 µm and then geometrically diluted with calcium carbonate or microcrystalline cellulose in a bin blender equipped with an intensifier bar; the intensifier bar is operated at 1200 rpm for 3 minutes per dilution step to break agglomerates without generating heat above 35 °C. The resulting premix is filled into antistatic polyethylene liners because electrostatic segregation can shift potency by more than 5% from the target in low-density cellulosic carriers. Use in food-producing avian species is not authorised under Regulation (EU) No 37/2010 and similar restrictions in other jurisdictions; this premix is therefore limited to zoological or quarantine collections where eggs and meat do not enter the human food chain. The workstream includes temporal separation from food-producing feed lines, dedicated scoops, and decontamination of bins with hot water and detergent followed by 70% isopropanol to reduce cross-contamination to below the carryover limit of 0.1% of a subsequent batch. In-process testing includes sieving through an 800 µm screen to reject pellets formed during storage and blend uniformity analysis at 10 sampling points with an acceptance value of 15 under pharmacopoeial requirements. Published efficacy data for amantadine premix in non-food avian influenza are limited to older experimental challenge studies; resistance-associated mutations in the M2 protein have reduced the current utility of adamantanes in many influenza A strains, and susceptibility confirmation is required before any quarantine use is considered.